CytomX
4 known investors
CytomX is a clinical-stage biopharmaceutical company developing Probody therapeutics, including antibody-drug conjugates (ADCs), aimed at treating cancer with more potent, less toxic medications. Its lead drug candidate targets colon cancer, and it has multiple Probody programs in clinical trials.
BiotechHealthtech
Investors Β· 4
Funding
SEC filings, press & company announcements- Undisclosed amountequity offeringMar 2026Source β
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - BioSpacebiospace.com Β· Aug 2026
CytomX Therapeutics (CTMX) posts Q2 loss, expands Regeneron cancer pactstocktitan.net Β· Aug 2026
CytomX Q2 Results: $37M Regeneron Payment, $330M Cash | CTMX Stock Newsstocktitan.net Β· Aug 2026
CytomX Therapeutics (NASDAQ: CTMX) swings to Q2 loss, adds $37M Regeneron feestocktitan.net Β· Aug 2026Frequently asked questions
- What does CytomX do?
- CytomX is a clinical-stage biopharmaceutical company developing Probody therapeutics, including antibody-drug conjugates (ADCs), aimed at treating cancer with more potent, less toxic medications. Its lead drug candidate targets colon cancer, and it has multiple Probody programs in clinical trials.
- Who are CytomX's investors?
- CytomX's investors include Canaan Partners, Longitude Capital, Pfizer Venture Investments, OrbiMed.